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The substantia gelatinosa (SG) of the spinal cord processes incoming painful 
information to ascending projection neurons. Whole-cell patch clamp recordings from 
SG spinal cord slices documented that in a low Ca2+/no Mg2+ (low X2+) external 
medium ATP/Dibenzoyl-ATP (Bz-ATP) caused inward current responses, much 
larger in amplitude than those recorded in a normal X2+-containing bath medium. The 
effect of Bz-ATP was antagonized by the selective P2X7 receptor antagonist A-
438079. Neuronal, but not astrocytic Bz-ATP currents were strongly inhibited by a 
combination of the ionotropic glutamate receptor antagonists AP-5 and CNQX. In 
fact, all neurons and some astrocytes responded to NMDA, AMPA and muscimol with 
inward current, demonstrating the presence of the respective receptors. The reactive 
oxygen species H2O2 potentiated the effect of Bz-ATP at neurons but not at 
astrocytes. Hippocampal CA1 neurons exhibited a behaviour similar to, but not 
identical with SG neurons. Although a combination of AP-5 and CNQX almost 
abolished the effect of Bz-ATP, H2O2 was inactive. A Bz-ATP-dependent and A-
438079-antagonizable ROS production in SG slices was proven by a microelectrode 
biosensor. Immunohistochemical investigations showed the co-localization of P2X7-
immunoreactivity with microglial (Iba1), but not astrocytic (GFAP, S100) or neuronal 
(MAP2) markers in the SG. It is concluded that SG astrocytes possess P2X7 
receptors; their activation leads to the release of glutamate, which via NMDA- and 
AMPA receptor stimulation induces cationic current in the neighbouring neurons. 
P2X7 receptors have a very low density under resting conditions but become 
functionally up-regulated under pathological conditions. 
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Introduction 
   The substantia gelatinosa (SG; layer II) of the spinal cord is an important area of 
sensory integration in the CNS, where incoming C and A fibre axons of the primary 
afferents innervate local interneurons, which process nociceptive information to 
ascending projection neurons originating in the layer I of the spinal cord (Furue et al., 
2004; Gu and Heft, 2004). The SG receives dense descending inhibitory serotonergic 
and noradrenergic inputs from the raphe magnus and locus coeruleus; the afferent 
terminals and interneurons contain excitatory substances such as substance P and 
calcitonin gene related peptide; high densities of excitatory and inhibitory 
interneurons in the SG utilize glutamate as excitatory and glycine/GABA as inhibitory 
transmitters (Brown, 1982; Furue et al., 2004). Many of these neuronal 
transmitters/modulators, including the endogenous nucleoside adenosine may 
regulate SG functions as shown by the patch clamp technique in spinal cord slice 
preparations (Lalo et al., 2004). 
   Adenosine is an active metabolite of the neuronal/glial signaling molecule ATP, 
which via various types of P2X receptors is involved in the processing and 
modulation of painful stimuli i.e. at the level of the spinal cord (Burnstock and Wood, 
1996; Wirkner et al., 2007b; Burnstock et al., 2011). P2X3 receptors located at the 
terminals of primary sensory afferents forming synapses with dorsal horn neurons of 
the SG (Nakatsuka et al., 2003) facilitate the release of the neurotransmitter 
glutamate and thereby enforce pain transmission (Gu and MacDermott, 1997). In 
addition, during neuropathic pain, astrocytic P2X7 and microglial P2X4/P2X7 
receptors lead to the release of inflammatory mediators causing hyperalgesia and 
allodynia (Tsuda et al., 2005; Burnstock et al., 2011).  
   P2X7 receptors have originally been identified at peripheral and central 
immunocytes such as macrophages, lymphocytes and microglia, where they mediate 
immediate necrosis and on a longer term either apoptosis or cell proliferation 
(Sperlágh et al., 2006). Although there is broad consensus that macroglial cells 
possess P2X7 receptors (Verkhratsky et al., 2009; Franke et al., 2012), there is an 
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ongoing dispute on the question whether this receptor-type is also present at 
peripheral and central neurons (Sim et al., 2004; Anderson and Nedergaard, 2006). 
The classic signaling mechanism of the P2X7 receptor-channels opened by 
pathologically high ATP concentrations involves the sustained elevation of the 
intracellular free Ca2+, several second messengers and enzyme cascades due to the 
drastic change in intracellular ion homeostasis, and the release of interleukin-1/nitric 
oxide (NO)/reactive oxygen species (ROS) (Sperlágh et al., 2006; Skaper et al., 
2010).  
   The questions we attempted to answer by the present study were the following: (1) 
Do spinal astrocytes in agreement with the supraspinal ones possess functional 
P2X7 receptors? (2) Do SG neurons respond to P2X7 receptor agonists directly or 
indirectly via signaling molecules secreted from neighbouring astrocytes? (3) Does 
astrocytic ROS modify the sensitivity of SG neurons to P2X7 receptor agonists? We 
tentatively suggest that spinal astrocytes contain P2X7 receptors whose activation 
leads to a release of glutamate and ROS which induce and facilitate, respectively, the 
ensuing current responses in neurons. 
 
 
Materials and Methods 
Brain slice preparation, whole-cell patch clamp recordings, and drug 
application protocols 
Wistar rat pups (11-14 days old) and in some cases transgenic mice expressing 
mRFP1 under the control of the human glial fibrillary acidic promoter 
(Tg(GFAP/mRFP1); 10-14 days old) were decapitated in order to prepare slices of 
their thoracolumbar spinal cord (Luo et al., 2002). The transgenic mice were a 
generous gift from Dr. Petra G. Hirrlinger (Paul-Flechsig-Institut für Hirnforschung, 
University of Leipzig) (Hirrlinger et al., 2005). All experiments were in accordance 
with the German guidelines for the use of animals in biomedical research. After 
decapitation, ventral laminectomy, followed by dorsal and ventral root transsection 
 6 
and in situ meninges removal was performed. The spinal cord was taken out and 
placed in ice-cold, oxygenated (95% O2 plus 5% CO2) artificial cerebrospinal fluid 
(aCSF) of the following composition (mM): NaCl 126, KCl 2.5, CaCl2 2.4, MgCl2 1.3, 
NaH2PO4 1.2, NaHCO3 25, and glucose 11; pH 7.4). Transverse slices with a 
nominal thickness of 200 m were cut from a piece of the lumbosacral spinal cord by 
using a vibratome (VT1200, Leica Biosystems). The slices were incubated for 30 min 
at 37°C in continuously aerated (95% O2 plus 5% CO2) aCSF. A single slice was 
placed in a recording chamber and superfused with oxygenated aCSF at room 
temperature (20-24oC) at a speed of 3 ml/min. The composition of the aCSF used for 
superfusion was identical with that used for incubation. To create low divalent cation 
(low X2+) conditions, MgCl2 was omitted from the medium and the CaCl2 
concentration was decreased to 0.5 mM.  
   Whole-cell patch clamp recordings were made after at least 60 min of superfusion 
with normal or low X2+ aCSF either from neurons or astrocytes of the SG of the spinal 
cord. Both types of cells were visualized with an upright interference contrast 
microscope and a x40 water immersion objective (Axioscope FS, Carl Zeiss). 
Astroglial cells of Tg(GFAP/mRFP1) mice were identified by means of an appropriate 
fluorescence filter of our microscope. Patch pipettes were produced by a horizontal 
micropipette puller (P-97, Sutter Instruments) from borosilicate capillaries. They were 
filled with intracellular solution of the following composition (mM): K-gluconic acid 
140, MgCl2 1, HEPES 10, EGTA 11, Mg-ATP 1.5, Li-GTP 0.3, and Lucifer Yellow 
(LY) 0.1; pH 7.3. Pipette resistances were in the range of 5-7 M.  
   The SG was clearly discernible as a relatively translucent band across the dorsal 
horn, somewhat below the surface of the spinal cord (Fig. 1Aa). After being filled with 
LY, fluorescence microscopy showed that neurons had round and sharply edged 
contours (Fig. 1Ab, upper panel), whereas astrocytes possessed many bushy 
processes (Fig. 1Ab, lower panel). Because both cell-types were of similar shape and 
size (diameter, 7 m), under our recording conditions, neurons could be 
discriminated from astrocytes only by their abilities to fire action potentials in the 
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current-clamp recording mode of the patch clamp amplifier (Multiclamp 700A, 
Molecular Devices). For this purpose hyper- and depolarizing current pulses of 
increasing amplitude (50-150 pA, depending on the membrane resistance) were 
injected into the respective cells. 
   The resting membrane potential (Vm) of the astrocytes was somewhat higher than 
that of the neurons. When the liquid junction potential of -15.2 mV (calculated VLJ 
between the bath and pipette solutions; Wirkner et al., 2007a) was used for 
correction, the Vm of a population of SG astrocytes and neurons was -86.43.7 mV 
(n=56) and -69.72.1 mV (n=38), respectively. The membrane resistance (Rm) of the 
astrocytes and neurons in the same population was 290.047.5 M and 699.275.1 
M, respectively. The rather high Rm values indicate that both cell types were small 
and astrocytes were probably not or only to a minor extent interconnected by low 
resistance pathways. Then, the holding potential of the astrocytes (-80 mV) and 
neurons (-70 mV) were set near to their resting membrane potential values in the 
voltage-clamp recording mode of the amplifier. A voltage-step protocol in the range of 
-80 to +30 mV for neurons and in the range of -160 to +60 mV for astroglial cells 
were used. Step duration was 500 ms, and steps were delivered with an interval of 2 
s. Cells where the series resistance (Rs) varied more than 20% during the 
experiments were discarded; there was no compensation for the Rs before recording 
was started.  
   Multiclamp and pClamp software (Molecular Devices) were continuously used to 
store the recorded data, to perform offline analysis/filtering and to trigger the 
application system used. All compounds were pressure-injected locally by means of a 
computer-controlled DAD12 superfusion system (Adams and List). The drug 
application tip touched the surface of the brain slice and was placed 100-150 m 
from the patched cell. Agonists were applied every 5 min for 10 s each, either at 
increasing (e.g. Fig. 2Aa, b) or stable concentrations (e.g. Fig. 1Bc, Ca, Da). When 
the interaction of Bz-ATP with excitatory amino acid (EAA), GABAA, or P2X7 receptor 
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antagonists was studied, a stable concentration of Bz-ATP was applied with the usual 
protocol before (S1, S2), during (S3, S4) and after superfusion (S5, S6) with these 
antagonists for 10 min (e.g. Fig. 3A-G). When the interaction of Bz-ATP with H2O2, N-
acetyl-L-cysteine (NAC) and catalase was studied, Bz-ATP was applied with a 
slightly modified protocol before, during and after superfusion with the ROS 
modulators (e.g. Fig. 5A-D). H2O2, NAC or catalase were applied 5 min after the first 
application of Bz-ATP (at S2), and were left in the superfusion medium for 10 min in 
total. Thus, 10 min elapsed between the first and second Bz-ATP injection (S1, S3), 
whereas only 5 min elapsed between the second and third Bz-ATP injection (S3, S4). 
Eventually, the protocol used to study the facilitation of Bz-ATP or ATP effects by a 
low X2+ medium, differed from the above standard procedure in that low X2+ was 
superfused for 10 min after S2 before the P2X7 receptor agonists were applied at S3 
for 10 s. Excised patches were prepared by slowly withdrawing the pipette and 
thereby separating the patch from the surrounding cells.  
   In some of the experiments, hippocampal slices of rats were prepared by 
procedures described earlier (Leichsenring et al., 2013). Whole-cell patch clamp 
recordings were made either from neurons of the CA1 region, or astrocytes from the 
oriens region in close apposition to CA1 (200 m distance). Compositions of the 
extra- and intracellular media were identical with those used for SG neurons and 
astrocytes. All further experimental conditions, including cell-type identification, 
recording arrangements, drug application protocols, and evaluation procedures were 
also similar.  
 
Biosensor measurements of reactive oxygen species 
300 µm thick coronal sections of the lumbosacral spinal cord were cut by using a 
vibratome. Tissue slices were stored in low X2+ aCSF under constant aeration with a 
mixture of 95% O2 and 5% CO2 for at least 45 min and then transferred to the slice 
chamber for measurement, with constant perfusion of standard aCSF at a speed of 3 
ml/min. After transferring spinal cord slices to the flow chamber, biosensors were 
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gently inserted into the tissue at the SG close to each other. After 5 min of 
equilibration, electrochemical recordings were started. Biosensor microelectrode 
measurements were carried out similarly as to previously published (Heinrich et al, 
2012) using ROS and NULL Pt/Ir microelectrode biosensors (sarissaprobes®, Sarissa 
Biomedical) with sensing tips of 50 µm in diameter and 0.5 mm in length. The surface 
of the ROS biosensors were deposited with superoxide dismutase and catalase 
enzymes to break down reactive oxygen species and served as interference controls 
to NULL sensors, which lacked these reductive enzymes. The net signal difference 
(NULL minus ROS) were calculated, and calibration curves (Figure 6A) were used to 
obtain relevant concentrations of in situ ROS.  
   Bz-ATP (300 µM) was superfused for 2 min. When applied, the P2X7 antagonist A-
438079 (10 µM) was pre-perfused for 10 min before BzATP stimulation. Using the 
calibration curve constructed from the net signal of known H2O2 concentrations 
ranging from 1-10 M (Figure 6A, inset), the maximal increases evoked by the drug 
treatments were read of at their peaks and were expressed in µM H2O2 equivalents. 
In 2 out of 8 slices (BzATP), and 1 out of 6 slices (BzATP plus A-438079) the 
treatments did not evoke detectable ROS release (no increase in net signal 
compared to baseline, therefore yielding negative maximal values); these values 
were not included in analysis.  
 
Immunofluorescence and confocal microscopy 
Rats were transcardially perfused under anesthesia with paraformaldehyde (2%) in 
sodium acetate buffer (pH 6.5; solution A) followed by paraformaldehyde (2%) in 
sodium borate buffer (pH 8.5; solution B) (Franke et al., 2004). Then, the brains were 
removed, stored overnight in solution B and 50 µm coronal sections of their 
hippocampal formation and the spinal cord containing the substantia gelatinosa were 
prepared using a vibratome (Leica). In some cases, spinal cord slices (100 µm 
thickness), kept in oxygenated aCSF for 2-3 h, similar to those used for 
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electrophysiological recordings, were processed for immunohistochemical 
investigations. 
   50 µm thick brain slices from transcardially perfused brains were incubated with 
antibody mixtures of rabbit anti-P2X7 (1:600; Alomone Labs) and/or with mouse anti-
GFAP (1:1,000; glial fibrillary acidic protein; Santa Cruz), or mouse anti-S100 
(1:600, S100 Protein Ab-1, Clone 4C4.9; Dianova), mouse anti-MAP2 (1:1,000; 
microtubule associated protein; Chemicon), as well as goat anti-Iba1 (1:50; goat 
polyclonal to Iba1; abcam) together with 0.3% Triton X-100 and 5% FCS in tris-
buffered saline (TBS) for 48 h at 4°C.  
   For the simultaneous visualisation of the different primary antibodies, mixtures of 
secondary antibodies specific for the appropriate species IgG (rabbit, mouse, goat) 
were applied. Carbocyanine (Cy)2- (1:400), Cy3- (1:1000), Cy5- (1:100) conjugated 
IgGs (all from Jackson ImmunoResearch) diluted in 0.3% Triton X-100 and 5% fetal 
calf serum (FCS) in TBS were applied, respectively, for 2 hours at room temperature. 
Control experiments were performed without all primary antibodies or by 
preadsorption of the antibody with the immunizing peptides. After mounting on glass 
slides, all stained sections were dehydrated in a series of graded ethanol, processed 
through n-butylacetate and coverslipped with Entellan (Merck).  
   The double and triple immunofluorescences were investigated by a confocal laser 
scanning microscope (LSM 510 Meta, Carl Zeiss) using excitation wavelengths of 
633 nm (helium/neon2, blue Cy5-labelling), 543 nm (helium/neon1, red Cy3-
immunofluorescence) and 488 nm (argon, yellow-green Cy2-immunofluorescence).  
 
Materials 
The following drugs were used: adenosine 5′-triphosphate disodium salt hydrate 
(ATP), catalase from bovine liver, hydrogen peroxyde (H2O2), N-acetyl-L-cysteine, N-
methyl-D-aspartic acid (NMDA), strychnine hydrochloride (Sigma-Aldrich); (S)-α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (S-AMPA), 2'(3')-O-(4-
benzoylbenzoyl)adenosine-5'-triphosphate tri(triethylammonium) salt (Bz-ATP), 3-[[5-
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(2,3-dichlorophenyl)-1H-tetrazol-1-yl]methyl]pyridine hydrochloride (A-438079), 6-
cyano-7-nitroquinoxaline-2,3-dione, D-(-)-2-amino-5-phosphonopentanoic acid, 
gabazine, muscimol (Tocris Bioscience). The pH value of the ATP-containing aCSF 
superfused onto the neurons/astrocytes was adjusted by NaOH to 7.4. 
 
Statistics 
   Concentration-response curves for agonists were fitted by using a three parametric 
Hill plot (SigmaPlot 11.0, SPSS). MeansS.E.M. are given throughout. SigmaPlot 
11.0 was used for statistical evaluation. Multipile comparisons between data were 
performed by one way analysis of variance followed by the Holm-Sidak test. Two 
data sets were compared by using the Student’s t-test or the Mann-Whitney Rank-
Sum test as appropriate. In all cases, a probability level of 0.05 or less was 
considered to be statistically significant. 
 
 
Results 
Current responses induced by Bz-ATP/ATP, glutamate, and GABA in 
astrocytes and neurons of the rat spinal cord substantia gelatinosa; mediation 
of ATP effects by P2X7 receptors 
   Initially the cell type recorded from (astrocyte or neuron) was identified. There was 
no discrimination between the different astrocytes described e.g. for the prefrontal 
cortex or the hippocampal oriens layer (outwardly rectifying, variably rectifying, 
passive; classification based on the current/voltage characteristics; e.g. Oliveira et 
al., 2011; Leichsenring et al., 2013), which were also present in the SG. In addition, 
we did not characterize the various types of neurons described for the SG (phasic, 
tonic, irregular, delay, transient; classification on the basis of the firing pattern and 
morphological properties; e.g. Grudt and Perl, 2002).  
   It was an important point to decide whether recordings are from astrocytes or 
microglia. Microglial cells in brain slices may exhibit morphological characteristics 
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somewhat similar to astroglia after LY filling and also fail to fire action potentials in 
response to depolarizing current injection (Fig. 1Ab, lower panel; compare Fig. 1Ba 
with Bb) (Boucsein et al., 2000). However, in voltage-clamp recordings, resting 
microglia express a typical inwardly rectifying current pattern and acquire an 
additional outwardly rectifying current component only after cell activation, for 
example, following facial nerve axotomy (Boucsein et al., 2000), status epilepticus 
(Ulman et al., 2013), or probably also the preparation of brain slices from living tissue 
(Fig. 8Cci). The astrocytes we recorded from, exhibited voltage-current 
characteristics clearly differing from those of the resting or activated microglia.  
   Then, we compared the Bz-ATP-sensitivity of rat SG neurons and astrocytes. At a 
holding potential of -80 mV, SG astrocytes responded to Bz-ATP (300 M) in the 
standard aCSF with only very small current responses (Fig. 1Bc, Ca, b). However, 
when the concentration of divalent cations was reduced or even abolished (0.5 mM 
Ca2+/no Mg2+; low X2+ medium), the effect of Bz-ATP markedly increased. Two 
subsequent applications of Bz-ATP (300 M) caused reproducible current responses, 
both in a normal and low X2+ medium. In addition, the potentiation induced by the 
lack of divalent cations rapidly reversed after returning to normal X2+ conditions. We 
evaluated both the absolute current amplitudes before, during and after superfusion 
with low X2+ aCSF (Fig. 1Ca) and the percentage increase of the Bz-ATP effects from 
S2 to S3 (Fig. 1Cb).  
   Similar results were obtained for SG neurons, although in this series of experiments 
the 2nd application of Bz-ATP (300 M; S4) in the presence of a low X
2+ medium 
caused less current than its 1st application (S3; Fig. 1Da). Nonetheless, the 
percentage increase of the Bz-ATP effect by a low X2+ external solution was 
comparable for astrocytes (to 2,304.3526.4%; n=6; P<0.05 from 0%) and neurons 
(to 2,279.21,286.8%; n=6; P<0.05 from 0%) (Fig. 1Cb, Db). It is noteworthy that 
both the Bz-ATP current amplitudes at low Ca2+/no Mg2+ and their percentage 
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increase under these conditions strongly varied between the individual neurons 
giving rise to considerable scatter around the means. 
   It is necessary to repeatedly point out that in contrast to SG astrocytes, SG neurons 
form a very inhomogenous population. The majority of SG neurons are excitatory, 
while their inhibitory counterparts represent a minority (Santos et al., 2007; Landry et 
al., 2004). It was also reported that supposedly glutamatergic, excitatory SG neurons 
are presynaptically inhibited by opioid µ-receptor agonists, while the inhibitory ones 
are opioid resistant (Santos et al., 2004). By contrast, purinergic P2X7 receptor 
agonists indiscriminately activated SG neurons, irrespective of their firing patterns 
(present study). However, differences in receptor-sensitivities may explain the large 
scatter in the current amplitudes. 
   Then, we tested the effect of the mother compound of Bz-ATP, ATP itself. Once 
again, ATP (3 mM) produced only small current responses in astrocytes and neurons 
in a normal aCSF, which however largely increased in the presence of a low X2+ 
medium (Fig. 1Ea, b). In agreement with the Bz-ATP experiments, the low X2+ 
extracellular solution appeared to cause a weaker potentiation of the ATP-induced 
currents in neurons (to 214.248.1%; n=6; P<0.05 from 0%) than in astrocytes (to 
426.495.4%; n=5; P<0.05 from 0%), although this difference did not reach the level 
of statistical significance (Fig. 1Eb).  
   In all subsequent experiments, a low X2+ extracellular medium was used 
throughout. Increasing concentrations of Bz-ATP (0.03-3 mM) and ATP (0.3-30 mM) 
(Fig. 2Aa, b) induced inward currents; the plots of the logarithmic agonist 
concentrations against the current amplitudes yielded the concentration-response 
curves shown in Fig. 2Ac and d. Both at astrocytes and neurons, Bz-ATP was much 
more potent than ATP itself. In addition, the maximum current amplitudes for ATP 
and Bz-ATP were similar at the astrocytes, but not at the neurons. The concentration-
response curve of ATP at the neurons was much more shallow and reached only a 
lower maximum than the comparable curve for Bz-ATP did (for the respective EC50 
and Emax values see the Legend of Fig. 2Ac, d). 
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   Because ATP is an early neural signaling molecule, we investigated the effects of 
prototypic excitatory and inhibitory transmitters in SG neurons and astrocytes. AMPA 
and NMDA were used to stimulate the respective ionotropic glutamate receptors, 
while muscimol was used to activate the GABAA receptor-channel. AMPA (1-100 M) 
elicited astrocytic/neuronal currents of amplitudes depending on the agonist 
concentration (Fig. 2Ba-c). It was absolutely clear that the size of the neuronal 
currents markedly surmounted that of the astrocytic ones (for the IC50 and Emax 
values see the Legend to Fig. 2Bc). Moreover, a near maximum was reached already 
at 10 M AMPA, without a further relevant change up to 100 M. In separate 
experiments, 100 M of AMPA, NMDA and muscimol were tested on the same 
astrocyte or neuron (Fig. 2Ca-c). The larger AMPA responses at neurons in 
comparison with astrocytes could be confirmed also under these conditions and in 
addition NMDA exhibited the same neuron/astrocyte activity ratio as AMPA (Fig. 2Ca, 
b). In spite of using a Mg2+-free (and low Ca2+) medium, which relieves the Mg2+-
block of the NMDA receptor-channel, NMDA was on both cell-types less active than 
AMPA. In contrast to the excitatory amino acid agonists, muscimol caused similar 
current amplitudes at neurons and astrocytes. Eventually, AMPA, NMDA and 
muscimol acted on all neurons investigated, but only at a subpopulation of astrocytes 
(Fig. 2Ca-c). Out of the total cell number of 9, 2 astrocytes reacted to none of the 
agonists, and a variably number of cells reacted to 1, 2 or 3 agonists (Fig. 2Cc). 
Hence, in contrast to the astrocyte preferring properties of Bz-ATP and ATP (Fig. 1B-
E), all amino acid transmitters (except muscimol) preferred neurons over astrocytes. 
This was evident, when the current amplitudes and/or the proportion of the activated 
cells were taken into consideration.  
   Then, we asked ourselves, whether Bz-ATP acts primarily at SG astrocytes (which 
in other regions of the CNS were repeatedly described to possess P2X7 receptors; 
Oliveira et al., 2011; Illes et al., 2012), or only indirectly, through the release of further 
signaling molecules or neurotransmitters stimulating neurons (which were often 
suggested to be devoid of P2X7 receptors; Sim et al., 2004; Sperlágh et al., 2006). 
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Our assumption, that Bz-ATP activates P2X7 receptors at astrocytes was confirmed 
in the following series of experiments. In the whole-cell configuration of recording, the 
highly selective P2X7 receptor antagonist A-438079 (1, 10 M) concentration-
dependently inhibited the effect of Bz-ATP (300 M) at astrocytes (Fig. 3Aa, b), and 
caused a maximal inhibition already at 1 M in neurons (Fig. 3Ba, b). No further 
efforts were undertaken to characterize the P2X receptor-type which mediated the 
Bz-ATP-sensitive, but A-438079-resistant part of the astrocytic current responses (10 
µM A-438079; 18.06.5%; n=10). A comparable residual current was found also in 
neurons (10 µM A-438079; 25.05.8%; n=10). Bz-ATP is an agonist at most P2X 
receptor-types (except P2X5 and -6), with particularly high potency at the P2X1,3 
receptors (Jarvis and Khakh, 2009). However, P2X1 or P2X3 are unlikely to be 
involved, since the Bz-ATP current did not exhibit desensitization, characteristic for 
these receptors.  
   However, Bz-ATP (300 M) induced inward current in excised patches prepared 
from all astrocytes and neurons investigated. In 4 astrocytes out of a population of 5, 
A-438079 (10 M) inhibited the small Bz-ATP current to 48.111.4% of its original 
height (P<0.05); in the residual astrocyte there was no change of the current 
amplitude at all (100.8%; Fig. 3Ca, b). Further, in 3 neurons out of a population of 6, 
A-438079 (10 M) also depressed the tiny Bz-ATP current to 59.86.8% of its 
original value (P<0.05%), whereas in the residual 3 neurons there was no statistically 
significant change (122.015.0%; P>0.05; Fig. 3Da, b). Thus, we confirmed that the 
majority of SG astrocytes possess P2X7 receptors and so do about one half of the 
SG neurons as well.  
   The astrocyte shown in Fig. 3Ea was classified as one belonging to the transient 
class, based on its current-voltage characteristics. The blockade of NMDA (AP-5, 50 
µM), AMPA (CNQX, 20 µM), GABAA (gabazine, 10 µM), and glycineA receptors 
(strychnine, 10 µM) almost abolished the Bz-ATP (300 µM)-induced currents in 
neurons, but did not alter the astrocytic responses (Fig. 3Eb, B, C). The co-
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application of CNQX and AP-5 appeared to cause less inhibition (to 41.611.9%; 
n=6) than that of CNQX, AP-5, gabazine and sychnine (to 20.96.7%; n=10; P>0.05), 
although this difference did not reach the level of statistical significance. It can be 
suggested, however, that glutamate is released by the stimulation of astrocytic P2X7 
receptors and that the Bz-ATP-induced currents at neurons are due to the effect of 
this glutamate. The additional involvement of GABA or glycine could not be proven in 
spite of using the selective antagonists gabazine and strychnine. 
 
Current responses induced by Bz-ATP in CA1 neurons of the hippocampus; 
mediation of ATP effects by astrocytic P2X7 receptors 
   In a previous study we reported for astrocytes of the hippocampal oriens layer that 
P2X7 receptors mediate current responses in a low X2+ external medium (Oliveira et 
al., 2011). Now we found that neighbouring CA1 neurons also respond to Bz-ATP 
with inward current in a low Ca2+/no Mg2+ aCSF; such a change in the composition of 
the normal aCSF led to a sudden increase of the Bz-ATP (300 M) currents (Fig. 
4Aa-c). A single neuron out of 8 (Fig. 4Aa) was unresponsive to Bz-ATP in a normal 
aCSF, whereas the residual 7 neurons exhibited a small current response under 
these conditions (Fig. 4Ab, c; 15.34.2 pA; n=7). It is noteworthy that CA1 pyramidal 
neurons of the hippocampus responded with very different current amplitudes to the 
same concentration of Bz-ATP when the scatter both within and between individual 
groups of experiments is taken into consideration (1,495.4995,3 pA, n=7 in Fig. 
4Ab; 2,438.9736.4 pA, n=5 in Fig. 4Bb; 865.8267.1 pA, n=7 in Fig. 4Cb).  
   Repetitive applications of Bz-ATP (300 µM) 5-times did not lead to a statistically 
significant reduction of the evoked current responses (Fig. 4Ca, b), although they had 
a tendency to decrease from S2 to S5. In consequence, we tested the effect of Bz-
ATP (300 µM) before, during and after superfusion with A-438079 (10 µM) (Fig. 4Da-
b). The abolition of the agonist effect under these conditions unequivocally proves 
that P2X7 receptors are involved. It is noteworthy that Bz-ATP-induced currents in 
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hippocampal stratum oriens astrocytes are also due to P2X7 receptor stimulation, as 
confirmed by investigating the interaction between Bz-ATP and A-438079 (10 µM) 
(Oliveira et al., 2011).  
 
Potentiation of neuronal responses to Bz-ATP in the spinal cord substantia 
gelatinosa but not the hippocampal CA1 area by H2O2 
   The repetitive application of Bz-ATP (300 M) to SG astrocytes induced stable 
current amplitudes with no change from the 2nd to the 5th application (S2-S5; Fig. 5Aa, 
b). In order to avoid any possible variability of the 1st response, all responses were 
normalized with respect to the 2nd Bz-ATP current. No comparable experiments were 
made to confirm the stability of the effect of Bz-ATP (300 M) at neurons, but there 
was no reason to assume that repetitive application results in a change of amplitude 
(see e.g. Fig. 3Ba). Then, Bz-ATP (300 M) was superfused both in the absence and 
the presence of H2O2 (100 M) onto astrocytes (Fig. 5Ba, b) and neurons (Fig. 5Bc, 
d). H2O2 did not induce any current on its own, however, strongly potentiated the 
neuronal, but not astrocytic Bz-ATP currents to 259.673.4% of their original 
amplitude (n=11; P<0.05). The antioxidant N-acetyl-L-cysteine (NAC; 10 mM) also 
failed to act by itself; it decreased, however, the Bz-ATP current in neurons (to 
51.68.7%; n=8; P<0.05) but not astrocytes (Fig. 5Bb, d). These results as a whole 
suggest that exogenous and endogenous ROS facilitate P2X7 receptor-mediated 
effects only in neurons. Interestingly, catalase (1,000 U/ml), which degrades ROS, 
failed to alter the Bz-ATP current responses either in neurons or in astrocytes (Fig. 
5Bb, d).  
   In analogy to the situation in the SG, a combination of AP-5 (50 µM) and CNQX (20 
µM) strongly depressed the effect of Bz-ATP (300 µM) in the CA1 region (Fig. 5Ca, 
b). Already AP-5 caused slight inhibition, which was increased by the further addition 
of CNQX (to 14.24.2%; n=6). Eventually, AP-5, CNQX and gabazine (10 µM) 
abolished the Bz-ATP-induced current (to 2.00.5%; n=8; P<0.05 in comparison with 
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AP-5 and CNQX only) (Fig. 5Cd) indicating that both glutamate and GABA are 
involved in the neuronal responses. However, in contrast to the reaction of SG 
neurons, the Bz-ATP (300 M) effects in CA1 neurons were insensitive to H2O2 (100 
M) and astrocytic currents were even depressed by this agent (Fig. 5Da, b).  
 
Measurement of the Bz-ATP-induced release of reactive oxygen species from 
the spinal cord substantia gelatinosa; mediation by P2X7 receptors 
Superfusion of SG slices with BzATP (300 µM) for 2 minutes elicited a slow increase 
of their net ROS production, which was partly reversible upon washout (Figure 6B). 
The maximal increase elicited by BzATP was 7.075±1.99 µM (n=6). Change of the 
perfusion solution with another one not containing Bz-ATP did not elicit any increase 
in net ROS production (n=3; data not shown). Preperfusion with the selective P2X7 
receptor antagonist A-438079 (10 µM) for 10 minutes per se failed to evoke 
detectable net ROS production (Fig. 6C; first half of the recording). The net ROS 
signal evoked by BzATP (300 µM) was significantly decreased in the presence of A-
438079 (10 µM) (Figure 6C; 1.3±0.57 µM; n=5; P<0.05 from the effect of Bz-ATP 
alone). 
 
Bz-ATP induced currents in substantia gelatinosa astrocytes of 
Tg(GFAP/mRFP1) mice 
Eventually, a few transgenic Tg(GFAP/mRFP1) mice were used to prove that Bz-ATP 
(300 µM) induces current responses in GFAP-expressing astrocytes of the SG (Fig. 
7). The selective P2X7 receptor antagonist A-438079 (10 µM) depressed the Bz-ATP 
current at S3 to 12.2±3.0% of its original amplitude (n=8; P<0.05). Because the 
GFAP-expressing astrocytes were unequivocally identified on the basis of their red 
fluorescence, recording was without any doubt from this population of astroglia.  
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P2X7 receptor-immunoreactivity at microglia, but not at astrocytes or neurons 
of the substantia gelatinosa 
Most experiments were performed on 50 µm thick SG slices, prepared from 
transcardially perfused rats, where P2X7 receptor-immunoreactivity (IR) was co-
localized with the microglial marker Iba1 (Fig. 8Ca-c), but not the astroglial markers 
GFAP or S100 (Fig. 8Aa-c; Fig. 8Ba-c), or the neuronal marker MAP2 (Fig. 8Da-c). 
We observed in all cases staining for the respective cell-type marker, in the first 
column of Fig. 8 (a), staining for P2X7 antibodies in its second column (b) and the 
merged staining for both types of antibodies in its third column (c). 
   Immunohistochemistry in the stratum oriens of hippocampal slices resulted in 
similar results, although the intensity of the staining was lower (not shown). In 
histological specimens, microglia were in a resting, inactive state as proven by their 
numerous cellular processes (Fig. 8Ca). When the same investigations were made 
on 100 µm thick SG slices superfused with aCSF for 2-3 h, thus, under conditions 
similar to those used for electrophysiological recordings, the quality of the 
immunohistochemistry pictures suffered from this treatments (Fig. 8Cci). The 
comparison of Fig. 8Cc with Cci shows that microglia was activated by the 
mechanical damage inflicted upon the living slices by the preparation procedure 
(round shape, no cellular processes). Microglia and astrocytes established often 
close spatial relationships.  
   It remains to be explained why P2X7 receptor-IR was not found on astrocytes in 
spite of convincing evidence for the presence of functional P2X7 receptors on this 
cell type (for functional measurements in spinal cord slices of Tg(GFAP/mRFP1 mice 
see Fig. 7). It is a well known fact that e.g. in the hippocampal CA1 area only ~15% 
of the astrocytic population stains for GFAP-IR (Bushong et al., 2002). Therefore, we 
also used the glial marker S100 for being able to label a partially overlapping 
population of astrocytes. However, the P2X7-IR was absent in astrocytes stained 
either for GFAP or S100. Hence, we assume that the low density of such receptors 
might be a reason for this finding; large Bz-ATP/ATP-induced currents could be 
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demonstrated only in a low X2+ external medium, which is known to greatly amplify 
P2X7 receptor function. 
 
 
Discussion 
The main finding of this study is that P2X7 receptors at SG astrocytes and neurons 
are functionally up-regulated by a low Ca2+/no Mg2+-containing external medium; it is 
suggested that these receptors participate in the development of inflammatory and 
neuropathic pain. In fact, the use of genetically modified mice that lack the P2X7 
receptor failed to develop pain following both inflammatory and neuropathic insults 
(Hughes et al., 2007). Furthermore, P2X7 receptor antagonists have been shown in 
animal studies to obliterate such types of chronic pain states (Carroll et al., 2009; 
Andó et al., 2010). The loss of P2X7 receptor antagonists to produce an 
antihyperalgesic effect in interleukin-1 knockout animals (Honore et al., 2009) 
confirmed that the release of interleukins mediated by P2X7 receptors is a key 
mechanism in inducing pain during inflammation. Eventually, in humans a genetic 
association between lower pain intensity and hypofunctional P2X7 receptors was 
reported to occur (Sorge et al., 2012).  
   Of course the above findings do not differentiate between P2X7 receptors at 
peripheral immunocytes and their counterparts at microglia, astrocytes and possibly 
neurons in the CNS. It has been reported that astrocyte-like satellite cells in sensory 
ganglia bear P2X7 receptors, whose activation may lead to the facilitation of pain-
sensing P2X3 receptors at the primary sensory afferents (Chen et al., 2012; 
Burnstock et al., 2011). After lipopolysaccharide priming, P2X7 receptors release 
interleukin-1 in the spinal cord to cause mechanical hyperalgesia (Clark et al., 
2010). These findings agree with the recently reported intimate interaction between 
astrocytes/microglia and neurons in various areas of the CNS. Especially astrocytic 
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and neuronal networks may communicate by gliotransmitters such as ATP and 
glutamate (Fellin et al., 2006), or cytokines, NO and ROS (Safiulina et al., 2006). 
   In a very first series of experiments, we demonstrated by means of 
electrophysiological methods that SG astrocytes are endowed with functional P2X7 
receptors, just like astrocytes in the cerebral cortex and hippocampal oriens layer 
(Nörenberg et al., 2010; Oliveira et al., 2011; Leichsenring et al., 2013). Although we 
did not perform this time a detailed pharmacological analysis, a few findings 
unequivocally prove that we deal with P2X7 receptors at SG astrocytes: (1) A low X2+ 
medium strongly accentuated the nucleotide-induced currents; (2) under these 
conditions, Bz-ATP was more potent than its mother compound ATP; and (3) the 
highly selective P2X7 receptor antagonist A-438079 almost abolished the effect of 
Bz-ATP (Sperlágh et al., 2006; Anderson and Nedergaard, 2006). In addition, SG 
neurons also responded to Bz-ATP and ATP, exhibiting some differences from their 
astrocytic effects. In the first line, the Bz-ATP-induced neuronal currents had a larger 
scatter around the mean than the astrocytic ones. Moreover, ATP, in contrast to Bz-
ATP caused only negligible current responses at SG neurons. 
   In view of the pertinent communication between astrocytes and neurons in various 
parts of the CNS, the question has arisen, whether the neuronal Bz-ATP/ATP effects 
are indirect, targeting originally astrocytes and transmitted to neurons by the release 
of a possible signaling molecule (Fellin et al., 2006; Safiulina et al., 2006). 
Specifically, P2X7 receptor activation at astroglia has been reported to release 
glutamate (Duan et al., 2003; Fellin et al., 2006), GABA (Wirkner et al., 2005) and 
ATP itself (Suadicani et al., 2006). By the use of selective antagonists for ionotropic 
glutamate (NMDA, AMPA) and GABA (GABAA) receptors we demonstrated that the 
neuronal Bz-ATP responses were strongly inhibited, although usually not abolished. 
By contrast, the corresponding astroglial responses remained unchanged in the 
presence of these antagonists. In addition, excised patches from most SG astrocytes 
continued to respond to Bz-ATP in an A-438079 antagonizable manner. Surprisingly, 
excised patches prepared from a subpopulation of SG neurons also retained an A-
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438079-antagonizable Bz-ATP effect. Excised patches are no longer in physical 
contact with the surrounding spinal cord tissue and therefore Bz-ATP currents should 
arise without contamination by signaling molecules of the neighbouring cells. We 
conclude that P2X7 receptors are located primarily at SG astrocytes; the 
subsequently released glutamate and possibly GABA activates such receptors at SG 
neurons and induce inward currents. A minor contribution of neuronal P2X7 receptors 
situated at some SG neurons has been shown as well. 
   ROS, such as superoxide anion, hydrogen peroxide and hydroxyl radicals are 
cytotoxic agents released e.g. by the oxidative burst of microglia in response to its 
activation processes. In addition, considerable evidence suggests that these species 
are able to act as cellular signaling molecules to regulate biological functions (Adler 
et al., 1999). In the CNS, H2O2 plays a role as an endogenous modulator of synaptic 
dopamine release (Chen et al., 2001), participates in the manifestation of synaptic 
plasticity (Knapp and Klann, 2002), and produces pain by reducing GABAergic 
inhibitory influence on SG neurons (Yowtak et al., 2011).  
   Hence, it was interesting to observe that H2O2 at a relatively low concentration of 
100 M markedly increased the Bz-ATP current at SG neurons, without causing any 
change in SG astrocytes. Correspondingly, when given alone, the antioxidant N-
acetyl-cysteine depressed the neuronal but not astrocytic response to Bz-ATP. Thus, 
the inactivation of endogenous ROS by N-acetyl-cysteine or the application of 
exogenous H2O2 had opposite effects, supporting a possible reaction chain which 
involves the activation of astrocytic P2X7 receptors at astrocytes, the subsequent 
production of ROS and finally the potentiation of the neuronal AMPA and/or NMDA 
receptor-mediated cationic fluxes. The following findings favour such a mode of 
action: (1) we found that Bz-ATP increases the production/release of ROS from SG 
slices, probably by stimulating astroglial P2X7 receptors. (2) ATP induced the 
generation of ROS in hippocampal astrocytes, albeit by P2Y1 and not P2X7 receptor 
stimulation, and increased the frequency of GABAA spontaneous synaptic currents in 
CA3 pyramidal neurons (Safiulina et al., 2006). (3) ROS generated in Schwann cells 
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contributed to the ATP-mediated negative feed-back mechanism controlling the 
quantal secretion of acetylcholine from motor nerve terminals (Giniatullin et al., 
2005). (4) Eventually, it has been concluded that ROS or reactive nitrogen species 
react with the lipoprotein cell membrane and may thereby indirectly alter the function 
of ionotropic transmitter receptors (Stojilkovic et al., 2013). A direct effect via the 
oxidation of critical cysteine residues (Cys-399 of the NR2A subunit, Choi and Lipton, 
2000; Cys-430 of the P2X2 subunit; Coddou et al., 2009) at certain receptors of e.g. 
the NMDA- or P2X-types is also possible.  
   At an early developmental stage ATP is definitely not the only, but probably the 
most powerful excitatory transmitter/signaling molecule in SG astrocytes. Astrocytes 
bear a number of pharmacological receptors including those for the excitatory amino 
acids glutamate (AMPA, NMDA) and the inhibitory amino acid GABA (GABAA) 
(Verkhratsky and Steinhäuser, 2000; Lalo et al., 2011). We found that AMPA and 
NMDA had larger effects in neurons than in astrocytes, whereas the GABAA receptor 
agonist muscimol had comparable activity to stimulate its neuronal and astrocytic 
receptors at a fixed concentration of 100 M. These findings are important in view of 
the well known excitotoxicity of glutamate and ATP exerted by the stimulation of 
ionotropic AMPA/NMDA and P2X7 receptors, respectively. In fact, the significance of 
these receptor-classes is increasingly recognized in stroke and neurodegenerative 
illnesses (Planells-Cases et al., 2006; Volonte et al., 2012; Köles et al., 2011). 
Similarly, they are involved in the spinal and supraspinal sensation of pain, especially 
in the case of neuronal damage (Bleakman et al., 2006; Planells-Cases et al., 2006; 
Burnstock et al., 2011). 
   In a low X2+ medium, CA1 hippocampal neurons also responded to Bz-ATP through 
P2X7 receptor-activation, in agreement with findings reported for astrocytes in the 
hippocampal oriens layer (Oliveira et al., 2011). However, in the hippocampus, CA1 
neurons did not possess P2X7 receptors; glutamate and GABA of astrocytic origin 
appeared to mediate the inward current response to Bz-ATP. Moreover, H2O2 failed 
to potentiate the Bz-ATP effect on neurons and even depressed it on astrocytes in 
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this area of the brain. These are intriguing findings, since ATP has been shown 
previously to release ROS from astrocytes in the hippocampus, although by P2Y1 
rather than P2X7 receptor activation, and subsequently facilitated the spontaneous 
GABA release onto CA3 pyramidal neurons (Safiulina et al., 2006). Thus, either the 
astrocytic P2 receptor-repertoire regulating ROS release varies in these two brain 
regions (P2X7 vs. P2Y1), or the terminals of GABAergic interneurons innervating CA3 
neurons possess ROS-sensitive P2Y1 receptors, while CA1 neurons are devoid of 
P2X7 receptors, and their ionotropic glutamate receptors are not modulated by ROS. 
   Although the present evidence convincingly shows that P2X7 receptors are located 
at SG astrocytes and become unmasked in a low X2+ medium to operate as a partner 
of SG neurons, the further participation of microglial P2X7 receptors as a third player 
on the stage cannot be excluded. The pathological function of microglia as a first 
defence barrier for all types of damage to the CNS is without question, but their roles 
in sensing and modulating neuronal activity as well as communicating with astrocytes 
has been only recently elucidated (Bezzi et al., 2001; Pascual et al., 2012). Thus, in 
response to various stimuli, microglia are activated and they release small molecules 
such as nitric oxid, trophic factors, cytokines, and all types of neurotransmitters 
including ATP (Färber and Kettenmann, 2005). Hence, microglia endowed with P2X7 
receptors may react to ATP and release interleukin-1 or tumor necrosis factor- 
(Shieh et al., 2014) directly influencing SG neuronal activities; microglia could also 
release ATP (Imura et al., 2013), which stimulates astrocytic P2X7 receptors and 
thereby induces a glutamate/GABA receptor-mediated interaction with the SG 
neurons.  
   In conclusion, we describe a P2X7 receptor-triggered interaction between 
astrocytes and neurons in the SG of the spinal cord dorsal horn. Under the present in 
vitro conditions this interaction operates only in a low Ca2+/no Mg2+ medium. Such 
alterations in the ionic composition of the extracellular fluid may increase the 
susceptibility for neuronal discharges/seizures (Heinemann et al., 1992) known to 
depend on P2X7 receptors (Engel et al., 2012) and resembling the 
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aetiology/pathogenesis of neuropathic pain. Hence, in accordance with the general 
view that P2X7 receptors, due to their activation by large concentrations of 
endogenous ATP, function only under pathophysiological conditions (Sperlágh et al., 
2006), in the present study Bz-ATP/ATP caused rather small membrane currents in a 
normal external ionic milieu. 
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FIGURE LEGENDS 
 
FIGURE 1: Visual and electrophysiological identification of neurons and astrocytes in 
the substantia gelatinosa (SG) of the thoracolumbar spinal cord; increase of Bz-ATP-
induced currents in a low X2+ external medium. A: Fluorescence/light microscopic 
picture of a horizontal section of the spinal cord. White arrow points to the SG (layer 
II) just below the superficial layer I (a). The framed part of a is shown at a higher 
magnification in b. An astrocyte filled with Lucifer Yellow (LY) diffusing from the 
intracellular solution for 15 min via the patch clamp pipette (left blurred cone) is 
shown under ultraviolet light illumination. The diffusion of LY is confined to a single 
cell excluding the existence of syntitial multicellular astrocytic structures. Whole-cell 
patch clamp measurements were used. B: Series of hyper- and depolarizing current 
pulses were supplied to measure whether the patched cell reacts with an action 
potential. Typical electrotonic voltage responses of an astroglial cell to current 
injection (a). Action potential firing of a neuron after injection of depolarizing current 
pulses above a certain threshold voltage (b). At a holding potential of -80 mV, Bz-
ATP (300 M) was applied 6 times (S1-S6) as described in the Methods section (c). 
C, D: Reversible increase of the Bz-ATP (300 M) current amplitude by a low X2+ 
external medium both in astrocytes (C) and neurons (D). The holding potential was  
-80 mV for astrocytes and -70 mV for neurons both in this and all subsequent 
experiments throughout. Absolute current amplitudes (a) and percentage increase of 
the current from S2 to S3 (b). E: A low X
2+ aCSF potentiated the ATP (3 mM)-induced 
current both at astrocytes and neurons. Absolute current amplitudes (a) and 
percentage increase of the current from S2 to S3 (b). MeanS.E.M of 6 experiments 
each in C-E. *P<0.05; statistically significant differences from S2.  
 
 
FIGURE 2. Comparison of the effects of ATP and Bz-ATP on neurons and astrocytes 
in the substantia gelatinosa of the thoracolumbar spinal cord; effects of excitatory and 
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inhibitory amino acid transmitters. Whole-cell patch clamp measurements were used. 
A: Concentration-response relationship for Bz-ATP (a) and ATP (b) in astrocytes at 
the indicated concentrations in a low X2+ aCSF; representative recordings. The 
experimental protocol is described in the Methods section. Plot of increasing 
logarithmic concentrations of AMPA against the nucleotide induced current, both for 
astrocytes (c) and neurons (d). It is noteworthy that in comparison with Bz-ATP, the 
concentration-response curve of ATP was shallower and exhibited a lower maximum 
at neurons. The calculated parameters of the curves were the following: astrocytes 
(Bz-ATP, EC50=237.5110.9 M, Emax=631.293.1 pA, n=10; ATP, 
EC50=2,635.2632.3 M, Emax=591.665.9 pA, n=10), neurons (Bz-ATP, 
EC50=247.436.6 M, Emax=457.130.7 pA, n=7; ATP, EC50=5,968.01,790.8 M, 
Emax=58.74.3 pA, n=4). B, C: Effects of AMPA, NMDA and muscimol on neurons 
and astrocytes in the substantia gelatinosa at a low X2+ external medium. B: 
Concentration-response relationship for AMPA. Representative recordings from 
astrocytes (a) and neurons (b). The experimental protocol is described in the 
Methods section. Plot of increasing logarithmic concentrations of AMPA against the 
nucleotide induced current in both cell-types (c). The calculated parameters of the 
concentration-response curve for AMPA were the following: astrocytes (EC50=5.92.2 
M, Emax=90.712.0, n=7), neurons (EC50=5.30.9 M, Emax=349.919.6 pA, n=5). C: 
Current responses to AMPA, NMDA and muscimol at 100 M each, in neurons (a) 
and astrocytes (b). MeanS.E.M. of the responsive cells out of the total cells of 9 
investigated (as indicated in the columns). The experimental protocol is described in 
the Methods section. AA, amino acid transmitters. The number of responsive cells is 
shown for the astrocytes (c). It is noteworthy that some cells did not react to any of 
the AA transmitters, while other ones reacted to 1, 2 or even all 3 transmitters.  
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FIGURE 3: Inhibition of Bz-ATP induced currents by A-438079 both in neurons and 
astrocytes of the substantia gelatinosa in a low X2+ external medium; blockade of Bz-
ATP effects by excitatory and inhibitory amino acid (AA) receptor antagonists in 
neurons but not astrocytes. Whole-cell patch clamp measurements were used in A, B 
and excised patches were prepared in C, D. Bz-ATP was applied 6 times (S1-S6) as 
documented by the original tracings and according to the protocol described in the 
Methods section. A: Depression by A-438079 (1 M) of the Bz-ATP (300 M)-
induced current in astrocytes. Representative recording in one cell (a). 
Concentration-dependent inhibition of the Bz-ATP (300 M)-induced current by A-
438079 (1, 10 M; b). Percentage meanS.E.M. change of the current amplitude 
from S2 to S3 at the indicated number of cells. B: Depression by A-438079 (1 M) of 
the Bz-ATP (300 M)-induced current in neurons. Representative recording in one 
cell (a). Concentration-dependent inhibition of the Bz-ATP (300 M)-induced current 
by A-438970 (1, 10 M; b). Percentage meanS.E.M. change of the current 
amplitude from S2 to S3 at the indicated number of cells. C, D: Excised patch 
experiments in astrocytes (C) and neurons (D) similar to those made under whole-
cell conditions. Representative recordings in one cell (a) and percentage 
meanS.E.M. change in the current amplitude from S2 to S3 at the indicated number 
of cells (b). All excised astrocytic patches responded to Bz-ATP, but only 4 out of 5 
astrocytes and only 3 out of 6 neurons exhibited A-438079-sensitivity. *P<0.05; 
statistically significant difference from the control current at S2. E-G: Inhibition of Bz-
ATP effects by excitatory and inhibitory amino acid (AA) receptor antagonists in 
neurons but not astrocytes. Voltage/current characteristics of an astrocyte generated 
by voltage steps from -160 to +60 mV in 20 mV increments from a holding potential 
of -80 mV (Ea). Combination of excitatory (AP-5, 50 µM; CNQX, 20 µM) and 
inhibitory (gabazine, strychnine, 10 µM each) (AA) receptor antagonists did not alter 
the Bz-ATP (300 µM) currents in astrocytes (Eb), but inhibited them in neurons (F). 
Representative recordings. G: MeanS.E.M. of the indicated number of experiments 
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performed in a similar manner as described for E and F. *P<0.05; statistically 
significant difference from the control current at S2. n.s.; no statistically significant 
difference between the two columns. 
 
 
FIGURE 4: Effect of Bz-ATP on hippocampal CA1 pyramidal cells and interaction 
with A-438079. Whole-cell patch clamp measurements were used. The holding 
potential was -70 mV in this Fig. and also in the next one. The same concentration 
(300 M) of Bz-ATP was applied 4-6 times (S1-S6; A, C, D) or increasing 
concentrations of this drug (10-1,000 M) were applied to construct concentration-
response relationships (B) as documented by the original tracings and according to 
the protocols described in the Methods section. A: Increase of the Bz-ATP (300 M)-
induced current amplitude by a low X2+ external medium. Representative recording 
(a). Absolute current amplitudes (b) and percentage increase of the current from S2 
to S3 (c). MeanS.E.M. of 7 experiments. *P<0.05; statistically significant differences 
from S2. B: Concentration-response relationship for Bz-ATP in a low X
2+ external 
medium. Representative recording (a) and plot of increasing logarithmic 
concentrations of Bz-ATP against the nucleotide-induced current (b). MeanS.E.M. 
of the current amplitudes in 5 experiments. The calculated parameters of the 
concentration-response curve for Bz-ATP were the following: EC50=96.06.5 M, 
Emax=2,658.295.2 pA, n=5). C: Reproducibility of the Bz-ATP (300 µM) current 
amplitudes during 4 applications (S2-S5; S1 discarded). Representative experiment 
(a) and percentage change with respect to S2 (b). There was no statistically 
significant difference between the individual current amplitudes. D: A-438079 (10 µM) 
abolishes the Bz-ATP (300 µM)-induced current. Representative experiment (a) and 
percentage change with respect to S2 (b). *P<0.05; statistically significant difference 
from S2. MeanS.E.M. of the indicated number of experiments in Cb and Db. 
 
 37 
 
FIGURE 5: Modulation of Bz-ATP-induced currents by H2O2 and its scavengers in 
neurons and astrocytes of the substantia gelatinosa, and in neurons of the 
hippocampal CA1 area in a low X2+ external medium; blockade of Bz-ATP effects in 
CA1 neurons by excitatory and inhibitory amino acid (AA) receptor antagonists. 
Whole-cell patch clamp measurements were used. A: Repetitive application of Bz-
ATP (300 M) causes stable current amplitudes in SG astrocytes. Representative 
experiment (a) and percentage meanS.E.M. change in the current amplitude from 
S2 to S5 at the indicated number of cells (b). There was no statistically significant 
difference between the currents between S2 and S5. B: Effects of H2O2 (100 M), N-
acetyl-L-cysteine (NAC; 10 mM) and catalase (CAT; 1,000 U/ml) on the astrocytic 
and neuronal Bz-ATP (300 M)-induced currents. Representative recordings 
demonstrate that H2O2 did not alter the effect of Bz-ATP in astrocytes (a), but 
facilitated it in neurons (c). There was no effect of H2O2 by its own on either cell type. 
Percentage meanS.E.M. change of the current amplitude from S2 to S3 by H2O2, 
NAC and CAT at the indicated number of astrocytes (b) or neurons (d). *P<0.05; 
statistically significant difference from S2. C: Combination of excitatory (AP-5, 50 µM; 
CNQX, 20 µM) and inhibitory (gabazine, 10 µM) AA receptor antagonists abolished 
the Bz-ATP (300 µM) currents in CA1 hippocampal neurons. Representative 
recording (a). MeanS.E.M. of the indicated number of experiments carried out 
during the sequential application of AP-5 (50 µM) and AP-5 plus CNQX (20 µM) (b) 
or AP-5, CNQX and gabazine (10 µM) together (c). D: H2O2 (300 µM) failed to alter 
the effect of Bz-ATP (300 µM) in neurons, but depressed it in astrocytes. 
Representative recording (a). MeanS.E.M. of the indicated number of experiments 
for neurons and astrocytes (b). *P<0.05; statistically significant difference from the 
current at S2. 
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FIGURE 6: Biosensor measurement of the production/release of reactive oxygen 
species (ROS) in rat substantia gelatinosa (SG) slices. A: Calibration curve and ROS 
biosensor traces showing responses to H2O2 (0.1-10 μM, net signal = ROS minus 
NULL, bottom). B: BzATP (300 μM, 2 minutes) induced ROS release. Black trace 
denotes the average of net signals while grey bars show S.E.M. (values in pA; n=6,; 
average of peak values correspond to 7.07 ± 1.99 μM ROS). C: Antagonistic effects 
of the P2X7 antagonist A-438079 (10 μM, 10 minutes) on BzATP-induced increase of 
ROS in the SG. Black trace denotes the average of net signals, while grey bars 
above show S.E.M. (values in pA; n=5; average of peak values correspond to 1.30 ± 
0.57 μM ROS). A-438079 did not alter the ROS release but antagonized the effect of 
Bz-ATP. 
 
 
FIGURE 7: Inhibition of Bz-ATP induced currents by A-438079 in astrocytes of the 
substantia gelatinosa in a low X2+ external medium; Tg(GFAP/mRFP1) mice were 
used in these series of experiments. Whole-cell patch clamp measurements at a 
holding potential of -80 mV. Bz-ATP was applied 6 times (S1-S6) as documented by 
the original tracings and according to the protocol described in the Methods section. 
A: Depression by A-438079 (10 M) of the Bz-ATP (300 M)-induced current in 
astrocytes. Representative recording in one cell. B: Inhibition of the Bz-ATP (300 
M)-induced current by A-438079 (10 M). Percentage meanS.E.M. change of the 
current amplitude from S2 to S3 and S4 at 8 cells. The effect of A-438079 was 
reversible on washout. The amplitude of the Bz-ATP-induced current at S2 was 
109.4±23.0 pA (n=8). *P<0.05; statistically significant differences from S2 (100%). 
 
 
FIGURE 8: Confocal images of multiple immunofluorescence labelling of rat 
substantia gelatinosa slices. Rats were either killed after perfusion fixation by 
decapitation, and their brains were immediately processed for immunohistochemistry, 
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or brain slices were at first incubated in aCSF for 2-3 h to imitate electrophysiological 
recording conditions, and immunohistochemistry procedures were only applied 
thereafter (Cci). No co-localization of glial fibrillary acidic protein- (GFAP; astrocytes; 
A), S100- (S100; astrocytes; B) and microtubule associated protein-2- (MAP-2; 
neurons; D) immunoreactivity (IR) with P2X7 receptor-IR was observed. In contrast, 
Iba1-IR (microglia) clearly co-localized with P2X7 (C). Comparison of Cci with Cc 
shows that the double staining for Iba1/P2X7 persists during conditions which imitate 
electrophysiological recordings. However, microglial cells lost their numerous cellular 
processes indicating activation by the preparation procedure. We used a 
homogenous color coding in A-D and a separate one in Cci. A-D: GFAP, S100, Iba1, 
MAP2 (green), P2X7 (red); Cci: Iba1 (green), P2X7 (red), GFAP (blue). Thin arrows 
indicate the P2X7-IR throughout. Scale bars for all panels, 20 µm. 
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